TUMOR TREATING FIELDS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Tumor Treating Fields Market, By Product Type (Transducer Arrays, Tumor Treating Field Generators, Others), By Indication (Glioblastoma Multiforme, Non-small Cell Lung Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Brain Metastasis, Others), By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments:

New product launches and approval:

In November 2022, Novocure GmbH, a Germany-based medical device company, announced that Health Canada has approved Optune for the treatment of newly diagnosed and recurrent glioblastoma (GBM).
In November 2020, Novocure GmbH announced that U.S. FDA had approved the NovoTTF-100L System (known as Optune Lua in the U.S.) as a treatment for malignant pleural mesothelioma (MPM).
In June 2020, Novocure GmbH announced the launch of MyLink, a new tool that allows patients to download their Optune usage data from the comfort of home without the need for an in-person visit by a Novocure Device Support Specialist.